Clinical Trials
67
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (67 trials with phase data)• Click on a phase to view related trials
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT07050459
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
- Conditions
- Malignant Ascites
- Interventions
- Drug: SIM0388
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07007988
- Locations
- 🇨🇳
Shanghai Gobroad Cancer Hospital, Shanghai, Shanghai, China
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SIM0505 for injection
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 172
- Registration Number
- NCT06792552
- Locations
- 🇨🇳
The first medical center of PLA general hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳HunanCancer Hospital, Changsha, Hunan, China
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: SIM0508 TabletsDrug: SIM0508 in combination with olaparib
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT06686745
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06680921
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next